The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Future role of CAR-T in AML
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the future role of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of acute myeloid leukemia (AML). In particular, Dr Haubner highlights the need to improve manufacturing and manage toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Sascha Haubner, MD, has received research support from Takeda Pharmaceutical Company Ltd.
